Sarepta Inks Global Licensing Deal With Arrowhead, Announces $500 Mln Share Buyback Program
In exchange, Arrowhead will receive an upfront payment of $500 million and an equity investment of $325 million in its common stock. The company will also receive $250 million in annual installments of $50 million over five years, along with milestone payments and royalties.
Arrowhead Pharma, Sarepta TX ink new gene therapy deal
Arrowhead Pharmaceuticals (ARWR) has secured a new partnership with Sarepta Therapeutics (SRPT). Under the terms of the deal, Sarepta will pay Arrowhead $500 million upfront and make a $325 million equity investment to gain access to Arrowhead's gene silencing technologies,
Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...
Arrowhead Pharmaceuticals has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics to develop ...
Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...
Sarepta Therapeutics said Tuesday that it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of ...
William Blair analyst Sami Corwin has maintained their bullish stance on SRPT stock, giving a Buy rating today.Don't Miss our Black Friday ...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...
Stocktwits on MSN20h
Arrowhead Pharma Stock Soars Pre-Market On $825M Sarepta Licensing Deal: Retail Activity Hits Year-HighShares of Arrowhead Pharmaceuticals ($ARWR) surged as much as 22% in pre-market trading on Tuesday after announcing a $825 ...
Sarepta Therapeutics and Arrowhead Pharmaceuticals teamed up on an siRNA partnership that has one of the biggest promises of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback